Cargando…
Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States
RATIONALE & OBJECTIVE: Information regarding disparities in initiating sodium/glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) in patients with chronic kidney disease (CKD) is limited. We examined sociodemographic and clinical factors associated...
Autores principales: | Zhao, Julie Z., Weinhandl, Eric D., Carlson, Angeline M., St. Peter, Wendy L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803841/ https://www.ncbi.nlm.nih.gov/pubmed/36593878 http://dx.doi.org/10.1016/j.xkme.2022.100564 |
Ejemplares similares
-
Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States
por: Zhao, Julie Z., et al.
Publicado: (2022) -
Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016
por: Zhao, Julie Z., et al.
Publicado: (2020) -
Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
por: Nicholas, Susanne B., et al.
Publicado: (2022) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017) -
Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
por: Nguyen, Hiep, et al.
Publicado: (2017)